CN103356545A - Application of Sarcaboside B in medicine used for treating ovarian cancer - Google Patents
Application of Sarcaboside B in medicine used for treating ovarian cancer Download PDFInfo
- Publication number
- CN103356545A CN103356545A CN 201310264148 CN201310264148A CN103356545A CN 103356545 A CN103356545 A CN 103356545A CN 201310264148 CN201310264148 CN 201310264148 CN 201310264148 A CN201310264148 A CN 201310264148A CN 103356545 A CN103356545 A CN 103356545A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- ovarian cancer
- application
- preparation
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses an application of Sarcaboside B in preparation of a medicine used for treating ovarian cancer and belongs to the technical field of new applications of medicines. In vitro MTT (methyl thiazolyl tetrazolium) antineoplastic activity evaluation shows that Sarcaboside B has an obvious inhibiting effect on growth of human ovarian cancer cell strains such as HO-8910, HOC1 and OVAC, so that Sarcaboside B can be used for preparing an anti-ovarian-cancer medicine and has a good development application prospect; the application of Sarcaboside B in preparation of the medicine used for treating ovarian cancer is disclosed for the first time, a brand new skeleton type is adopted, and Sarcaboside B has an unexpected inhibitory activity on human ovarian cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside B, relate in particular to the application of Sarcaboside B in the preparation ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound S arcaboside B that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes of the Sarcaboside B that the present invention relates in preparation treatment ovarian cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside B in the preparation ovarian cancer resistance medicament, and the structural formula of Sarcaboside B is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation Sarcaboside B also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50Value is respectively 1.22 ± 0.04 μ M, 1.31 ± 0.02 μ M and 2.11 ± 0.04 μ M.Therefore, Sarcaboside B can for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Sarcaboside B that the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously ovarian cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound S arcaboside B involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside B tablet involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside B capsule involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Sarcaboside B to human oophoroma cell line's growth inhibited effect
1. method: the cell that is in the growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside B has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This chemical compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50Value is respectively: 1.22 ± 0.04 μ M, 1.31 ± 0.02 μ M and 2.11 ± 0.04 μ M.
Shown that by above-described embodiment Sarcaboside B of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove that thus Sarcaboside B of the present invention has the ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
1.Sarcaboside the application of B in treatment ovarian cancer medicine, described compound S arcaboside B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310264148 CN103356545A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310264148 CN103356545A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356545A true CN103356545A (en) | 2013-10-23 |
Family
ID=49359367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310264148 Pending CN103356545A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356545A (en) |
-
2013
- 2013-06-27 CN CN 201310264148 patent/CN103356545A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872075A (en) | Application of Houttuynoid E in drugs for treating breast cancer | |
| CN102872086A (en) | Application of Houttuynoid A in medicines for treating skin cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103356538A (en) | Application of Sarcaboside A in preparation of drug for treating ovarian cancer | |
| CN103356531A (en) | Application of Sarcaboside B in medicine used for treating cervical cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103356589A (en) | Application of Sarcaboside A in preparation of drug for treating cervical cancer | |
| CN103356541A (en) | Application of Sarcaboside B in medicine used for treating gastric cancer | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103371996A (en) | Application of Sarcaboside A in medicine for treating nasopharynx cancer | |
| CN103356561A (en) | Application of Sarcaboside B in medicine used for treating renal cancer | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356535A (en) | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer | |
| CN103356559A (en) | Application of Sarcaboside B in preparation of medicines for treating tongue cancer | |
| CN103356571A (en) | Application of Sarcaboside B in preparation of medicines for treating nasopharynx cancer | |
| CN103356585A (en) | Application of Sarcaboside B in preparation of medicines for treating bladder cancer | |
| CN103356547A (en) | Application of Sarcaboside A in preparation of drug for treating skin cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |